Literature DB >> 17492633

Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus.

Gábor Wittmann1, Levente Deli, Imre Kalló, Erik Hrabovszky, Masahiko Watanabe, Zsolt Liposits, Csaba Fekete.   

Abstract

Type 1 cannabinoid receptor (CB1) is the principal receptor for endocannabinoids in the brain; it mainly occurs in preterminal/terminal axons and mediates retrograde neuronal signaling mechanisms. A large body of physiological and electrophysiological evidence indicates the critical role of CB1 in the regulation of hypothalamic functions. Conversely, the distribution of CB1-containing axons in the hypothalamus is essentially unknown. Therefore, we have analyzed the distribution and the ultrastructural characteristics of the CB1-immunoreactive (IR) axons in the mouse hypothalamus by using an antiserum against the C-terminal 31 amino acids of the mouse CB1. We found that CB1-IR axons innervated densely the majority of hypothalamic nuclei, except for the suprachiasmatic and lateral mammillary nuclei, in which only scattered CB1-IR fibers occurred. CB1-IR innervation of the arcuate, ventromedial, dorsomedial, and paraventricular nuclei and the external zone of the median eminence corroborated the important role of CB1 in the regulation of energy homeostasis and neuroendocrine functions. Ultrastructural studies to characterize the phenotype of CB1-IR fibers established that most CB1 immunoreactivity appeared in the preterminal and terminal portions of axons. The CB1-IR boutons formed axospinous, axodendritic, and axosomatic synapses. Analysis of labeled synapses in the paraventricular and arcuate nuclei detected approximately equal numbers of symmetric and asymmetric specializations. In conclusion, the study revealed the dense and differential CB1-IR innervation of most hypothalamic nuclei and the median eminence of the mouse brain. At the ultrastructural level, CB1-IR axons established communication with hypothalamic neurons via symmetric and asymmetric synapses indicating the occurrence of retrograde signaling by endocannabinoids in hypothalamic neuronal networks. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492633     DOI: 10.1002/cne.21383

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  35 in total

1.  Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus.

Authors:  Jaclyn I Wamsteeker; J Brent Kuzmiski; Jaideep S Bains
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 2.  Endocannabinoids and the Endocrine System in Health and Disease.

Authors:  Cecilia J Hillard
Journal:  Handb Exp Pharmacol       Date:  2015

3.  Type 1 cannabinoid receptor-containing axons innervate hypophysiotropic thyrotropin-releasing hormone-synthesizing neurons.

Authors:  Levente Deli; Gábor Wittmann; Imre Kalló; Ronald M Lechan; Masahiko Watanabe; Zsolt Liposits; Csaba Fekete
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

Review 4.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 5.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

6.  Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area.

Authors:  Alex Villanueva; Sertac M Yilmaz; William R Millington; Rodolfo A Cutrera; David G Stouffer; Loren H Parsons; Joseph F Cheer; Carlos Feleder
Journal:  Shock       Date:  2009-12       Impact factor: 3.454

Review 7.  Cannabinoid signalling and effects of cannabis on the male reproductive system.

Authors:  Mauro Maccarrone; Cinzia Rapino; Felice Francavilla; Arcangelo Barbonetti
Journal:  Nat Rev Urol       Date:  2020-11-19       Impact factor: 14.432

Review 8.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 9.  Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.

Authors:  Renato Malcher-Lopes; Alier Franco; Jeffrey G Tasker
Journal:  Eur J Pharmacol       Date:  2008-01-31       Impact factor: 4.432

Review 10.  Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.

Authors:  Helen Butler; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2009-09-03       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.